Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Anglesio

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Clinical Obstetrics and Gynecology|October 10, 2017
Endometriosis-associated Ovarian CancersMichael S Anglesio, Paul J Yong
The Journal of Pathology. Clinical Research|July 14, 2018
You won't believe this old test … that does cheap single-cell mutation detectionMartin Köbel, Michael S Anglesio, James D Brenton
Reproductive Sciences (Thousand Oaks, Calif.)|January 20, 2021
Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to PhenotypingPaul J Yong, Aline Talhouk, Michael S Anglesio
Journal of Cancer Research and Clinical Oncology|August 7, 2019
Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancerSabine Heublein, Michael S Anglesio, Frederik Marmé, et al.
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 11, 2020
Pathogenesis of bowel endometriosisPaul J Yong, Mohamed A Bedaiwy, Fahad Alotaibi, et al.
Sexual Medicine Reviews|August 6, 2023
Neuroproliferative dyspareunia in endometriosis and vestibulodyniaAgnes N Mwaura, Nisha Marshall, Michael S Anglesio, et al.
Gynecologic Oncology|February 1, 2011
Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010Michael S Anglesio, Mark S Carey, Martin Köbel, et al.
Histopathology|July 27, 2017
Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primariesMichael S Anglesio, Ciaran J O'Neill, Janine Senz, et al.
Nanomedicine (London, England)|April 22, 2014
Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatmentsAda W Y Leung, Jessica Kalra, Nancy Dos Santos, et al.
Histopathology|October 17, 2018
Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcomeLinyuan Wang, Peter F Rambau, Linda E Kelemen, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Clinical Obstetrics and Gynecology|October 10, 2017
Endometriosis-associated Ovarian CancersMichael S Anglesio, Paul J Yong
The Journal of Pathology. Clinical Research|July 14, 2018
You won't believe this old test … that does cheap single-cell mutation detectionMartin Köbel, Michael S Anglesio, James D Brenton
Reproductive Sciences (Thousand Oaks, Calif.)|January 20, 2021
Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to PhenotypingPaul J Yong, Aline Talhouk, Michael S Anglesio
Journal of Cancer Research and Clinical Oncology|August 7, 2019
Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancerSabine Heublein, Michael S Anglesio, Frederik Marmé, et al.
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 11, 2020
Pathogenesis of bowel endometriosisPaul J Yong, Mohamed A Bedaiwy, Fahad Alotaibi, et al.
Sexual Medicine Reviews|August 6, 2023
Neuroproliferative dyspareunia in endometriosis and vestibulodyniaAgnes N Mwaura, Nisha Marshall, Michael S Anglesio, et al.
Gynecologic Oncology|February 1, 2011
Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010Michael S Anglesio, Mark S Carey, Martin Köbel, et al.
Histopathology|July 27, 2017
Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primariesMichael S Anglesio, Ciaran J O'Neill, Janine Senz, et al.
Nanomedicine (London, England)|April 22, 2014
Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatmentsAda W Y Leung, Jessica Kalra, Nancy Dos Santos, et al.
Histopathology|October 17, 2018
Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcomeLinyuan Wang, Peter F Rambau, Linda E Kelemen, et al.
Pageof 9